Mirtazapin Beta (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Beta, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders by modulating noradrenergic and serotonergic pathways. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Depressive episodes with insomnia: enhances sleep quality while treating depression. - Depression with anxiety features: reduces anxiety symptoms associated with depressive states.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (including rash, angioedema) - Suicidal thoughts or behavior - Hepatic dysfunction - Uncontrolled hypertension

When prescribing Mirtazapin Beta, clinicians should consider several safety measures. - Hepatic function: assess liver status before initiation and monitor periodically. - Weight monitoring: counsel patients about potential weight gain and monitor BMI. - Elderly patients: use caution due to increased risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena; taper as advised. - Concomitant CNS depressants: evaluate additive sedative effects. - Pregnancy and lactation: prescribe only if benefit outweighs potential risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mirtazapin Beta can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): increased serotonin syndrome risk. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Antihypertensive drugs: additive hypotensive effect; monitor blood pressure.